- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Not So Different: Steven C. Hill, PhD, Discusses Rebates and Specialty Drug Spending
In an interview with The Center for Biosimilars®, Steven C. Hill, PhD, a senior economist with the Agency for Healthcare Research and Quality, discusses a recent study he co-authored on specialty drug spending.
In a recent study, investigators focused on net spending on specialty medicine after manufacturer rebates. What they found was a sharp rise in net specialty drug spending, but they also noted that use of rebates was rapidly increasing, too. This was true for both public and private payers. We discussed these findings with lead study author Steven C. Hill, PhD, a senior economist with the Division of Research and Modeling, Center for Financing, Access and Cost Trends, at the Agency for Healthcare Research and Quality in Rockville, MD.
To learn more about this study, click here.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Biosimilars Policy Roundup for March 2023—Podcast Edition
April 2nd 2023On this episode of Not So Different, we discuss some of the global biosimilar policy news that came out during the month of March, including a new bill in Congress and 2 Canadian jurisdictions implementing switching policies.
AAM's Craig Burton: Is the Biden Administration Doing Enough to Help Biosimilars?
November 13th 2022Craig Burton, senior vice president of policy and strategic alliances at the Association for Accessible Medicines and executive director of the Biosimilars Council, gives insight into the many health policies that the Biden administration has implemented in 2022 as well as their possible impact on biosimilar adoption.
